Ilyang Pharmaceutical’s Supect shows high generic response than Glivec

A phase III clinical trial result of ‘Supect(radotinib),’ the Asia’s first leukemia treatment developed by Ilyang Pharmaceutical, was published an online-version of an international journal ‘Clinical Cancer Research,’ on the 22^nd of September. The medical journal published a treatment result of first-diagnosed chronic myeloid leukemia patients conducted at 24 university hospitals in 5 Asian cou...